Merit Medical Q2 adjusted EPS beats estimates, raises 2026 outlook

Merit Medical Systems

30/07/2026 21:30

Overview
U.S. medical device maker's Q2 revenue rose 10% yr/yr, organic constant currency revenue up 9%
Adjusted EPS for Q2 beat analyst expectations
Company raised 2026 revenue and non-GAAP EPS guidance after strong H1 performance

Outlook
Merit raises 2026 revenue guidance to $1.631-$1.643 bln from $1.612-$1.634 bln
Company lifts 2026 non-GAAP EPS forecast to $4.25-$4.35 from $4.01-$4.15
Merit says 2026 guidance excludes potential impacts from trade policies and material acquisitions

Result Drivers
U.S. SALES GROWTH - Co said revenue growth was driven by notable strength in U.S. sales, which increased 10% yr/yr and exceeded expectations
MARGIN IMPROVEMENT - Co reported higher non-GAAP operating margin and non-GAAP EPS, citing improved profitability
PRODUCT SEGMENT GROWTH - Therapeutic Cardiac Therapies, Endoscopy, and OEM segments saw double-digit revenue growth yr/yr

Company press release: ID:nGNX5fF0DD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$1.19
$0.96 (10 Analysts)
Q2 EPS
 
$0.65
 
Q2 Adjusted Net Income
Beat
$71.30 mln
$58.70 mln (10 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Merit Medical Systems Inc is $90.00, about 11.3% above its July 29 closing price of $80.84
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
July 29 - Conmed Q2 sales, adjusted profit beat on organinc platform growth
July 29 - Boston Scientific Q2 results beat estimates on cardiovascular strength 
July 30 - Baxter Q2 revenue rises 5%, beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)